BioCatalystWatch
BCYCWorkspace / BCYC / OverviewCompany library
BICYCLE THERAPEUTICS PLC logo

BICYCLE THERAPEUTICS PLC

BICYCLE THERAPEUTICS PLC (BCYC)

Website

Price
Market cap
Next catalystExpected 2H 2027zelenectide pevedotin — Duravelo-2 · Phase 2 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

BT1702

MT1-MMP

Upcoming / outlook

zelenectide pevedotin

Nectin-4

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

zelenectide pevedotin

Nectin-4

PreINDP1P2P3FilingApproved
Upcoming / outlook

BT1702

MT1-MMP

Upcoming / outlook

Other pipelines

EphA2 BRC molecule

EphA2

Upcoming / outlook

zelenectide pevedotin

Nectin-4

PreINDP1P2P3FilingApproved

Partner / License out

PreINDP1P2P3FilingApproved

History / paused

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

BCYC PR & News

PR & News

BCYC SEC archive